HC Wainwright Cuts Shattuck Labs Price Target to $14, Maintains Buy Rating

Key Facts

Amid a broader reassessment of biotech valuations, HC Wainwright has lowered its price target for Shattuck Labs from $18.00 to $14.00. Despite the reduction, the firm maintained its "Buy" rating on the stock, signaling continued confidence in the company's long-term prospects. The adjustment follows the company's latest financial report, which showed a quarterly loss per share of $0.12, matching analyst expectations.

The decision to trim the price target reflects a more cautious outlook driven by concerns over valuation, low profitability, and observed insider selling trends. However, the company's ongoing development of innovative therapies remains a core pillar for the maintained Buy rating according to analyst reports. This move highlights the delicate balance between clinical progress and financial sustainability in the current market environment.

Based on authoritative data, specific closing price levels for STTK are currently unavailable, suggesting investors should focus on qualitative price direction in upcoming sessions. Looking ahead, the market will monitor US Initial Jobless Claims on August 6, 2026, as a potential catalyst for broader market sentiment that could impact growth-oriented sectors like biotechnology.